Inhibition of both paracrine and autocrine VEGF/ VEGFR-2 signaling pathways is essential to induce long-term remission of xenotransplanted human leukemias - sprookjes - yvandenbroek - TriplyDB

Inhibition of both paracrine and autocrine VEGF/ VEGFR-2 signaling pathways is essential to induce long-term remission of xenotransplanted human leukemias

Inhibition of both paracrine and autocrine VEGF/ VEGFR-2 signaling pathways is essential to induce long-term remission of xenotransplanted human leukemias

http://www.wikidata.org/entity/Q33943905

about

The progress of angiogenic factors in the development of leukemias Bone Marrow Blood Vessels: Normal and Neoplastic Niche Vascular endothelial growth factor mediates intracrine survival in human breast carcinoma cells through internally expressed VEGFR1/FLT1 Roles of the endogenous VEGF receptors flt-1 and flk-1 in astroglial and vascular remodeling after brain injury Blockade of VEGFR1 and 2 suppresses pathological angiogenesis and vascular leakage in the eye Vascular endothelial growth factor as an anti-angiogenic target for cancer therapy Sunitinib in relapsed or refractory diffuse large B-cell lymphoma: a clinical and pharmacodynamic phase II multicenter study of the NCIC Clinical Trials Group.Clinical relevance of vascular endothelial growth factor (VEGFA) and VEGF receptor (VEGFR2) gene polymorphism on the treatment outcome following imatinib therapy.Vascular endothelial growth factor-related pathways in hemato-lymphoid malignancies.Vascular endothelial growth factor receptor-2 in breast cancer.Leukemia regression by vascular disruption and antiangiogenic therapy.DNA methylation regulates expression of VEGF-R2 (KDR) and VEGF-R3 (FLT4).Instructive role of the vascular niche in promoting tumour growth and tissue repair by angiocrine factors.Functional proteomic profiling of AML predicts response and survival Butyrate-rich colonic microenvironment is a relevant selection factor for metabolically adapted tumor cells.Vascular endothelial growth factor (VEGF), a survival factor for tumour cells: implications for anti-angiogenic therapy.Activation of the vascular niche supports leukemic progression and resistance to chemotherapy Prognostic roles of cross-talk between peritumoral hepatocytes and stromal cells in hepatocellular carcinoma involving peritumoral VEGF-C, VEGFR-1 and VEGFR-3.Antiangiogenic agents targeting vascular endothelial growth factor and its receptors in clinical development.Dose study of the multikinase inhibitor, LY2457546, in patients with relapsed acute myeloid leukemia to assess safety, pharmacokinetics, and pharmacodynamics Does Chemotherapy Change Expression of VEGF A&C and MVD in Acute Myeloid Leukemia?Contribution of bone microenvironment to leukemogenesis and leukemia progression.The role of VEGF in normal and neoplastic hematopoiesis.VEGF blocking therapy in the treatment of cancer.The therapeutic potential of novel antiangiogenic therapies.VEGF is essential for the growth and migration of human hepatocellular carcinoma cells.The growth and aggressive behavior of human osteosarcoma is regulated by a CaMKII-controlled autocrine VEGF signaling mechanism Crosstalk between peroxisome proliferator-activated receptor delta and VEGF stimulates cancer progression Monoclonal antibody therapeutics and apoptosis.TTAC-0001, a human monoclonal antibody targeting VEGFR-2/KDR, blocks tumor angiogenesis.Enhanced natural-killer cell and erythropoietic activities in VEGF-A-overexpressing mice delay F-MuLV-induced erythroleukemia Manipulating angiogenesis in medicine.Generation of a syngeneic mouse model to study the effects of vascular endothelial growth factor in ovarian carcinoma.Pivotal role of vascular endothelial growth factor pathway in tumor angiogenesis.Mechanisms controlling pathogenesis and survival of leukemic stem cells.Functional VEGF and VEGF receptors are expressed in human medulloblastomas Survival of chronic lymphocytic leukemia cells: CD40L and the vascular endothelial growth factor (VEGF) connection.A Phase I Dose Escalation Study of the Triple Angiokinase Inhibitor Nintedanib Combined with Low-Dose Cytarabine in Elderly Patients with Acute Myeloid Leukemia.The effect of bevacizumab on human malignant melanoma cells with functional VEGF/VEGFR2 autocrine and intracrine signaling loops.Expression of vascular endothelial growth factor and its receptors KDR and Flt-1 in gastric cancer cells.

P2860

Q26753835-F2F43285-CAA3-408A-88FB-1D8FAD604689 Q28067400-42686DEC-EF42-40AB-AC5C-CF8D52C657A0 Q28469224-C6B9F20D-752F-4058-B241-8CB27B822816 Q28575249-CE9D224F-954C-40CB-AECF-D82C6C601A0A Q28743307-B66D14AB-D973-46E9-B97B-5C39F35FBF57 Q30455612-EDC0778E-2AF4-495D-86BE-8AB982E5526F Q33394774-E97341DA-3E03-4389-8154-483B267964A0 Q33513801-3FD5BCDB-4BF2-43F7-A6E4-932811AADC51 Q33874179-A42E850F-2260-412A-B1E6-04DBCBA589D0 Q33912620-3505C73A-B8AF-4A15-BD27-1F48A4F4C716 Q34124965-4A6C1CDD-320E-4BCD-981F-1B0571EEB8A0 Q34129693-9D10A8C1-03C7-423F-980E-2118BFF3B7B6 Q34152009-900C583E-F416-407A-B0FA-63766DFAFF17 Q34184598-BC616403-6AD1-4BE6-8E1A-A2E6F8002883 Q34385792-61D0FE54-3320-46CA-A1AF-F303766106EF Q34561521-4FE00893-6760-44E6-A685-4E8DD6B9DD1D Q34622824-03A8A5F8-5CDB-4EF7-B62C-D1B8233590CF Q34758849-F8237A96-F65D-422E-87C5-D03FE5B76C57 Q34974876-7EE50AE6-C6C7-4066-9D62-B1D4E64EC918 Q35003666-17DF5165-4566-44DC-91EA-0F9D92F99D74 Q35009275-43B2FB2E-A806-4772-B46A-960ECEEA700A Q35037058-81F0913D-01C0-4B80-8298-F1B2EE2D89E8 Q35052515-567A397D-634A-4ABA-9288-3D4176F79344 Q35093616-9E24210A-3F74-4A9D-9150-53DEFDBD4959 Q35143984-D046AA01-2158-4E40-A107-7B3597F5881B Q35162649-C998F314-0C5A-4BCA-88CB-EB4E7BF2ED0E Q35362682-925868C8-3B00-4911-B750-52E3C347D543 Q35539784-5467E788-47E4-4F2E-BB84-608EB24A6839 Q35603396-386BA7B4-C24F-4E83-A163-B82B01A7567A Q35622461-052E0DFD-6551-44C2-B662-D1DCCB13628F Q35642763-54BB0C25-731B-430E-B637-1DB09E89790C Q35743851-97CEFAB6-53BC-4283-B10E-C7288ABFBA5F Q35748149-34B759C9-CCF0-4E47-95B5-5A5E58F81571 Q35782469-D1AA2C09-E740-4978-854E-65E9D38AA097 Q35892084-5501DF5B-071F-4FB7-B78F-FCE94DD3F387 Q36013314-C19A628A-04A3-41CB-9BC4-5211D2D5727A Q36110555-7D02000F-B02C-46ED-BD91-F249591830A8 Q36157664-82D0371D-D974-4C1D-9514-47C4E200D2E7 Q36172732-79B33EE3-7080-4ED4-83FB-A2E63C4C4442 Q36308484-7F0D3F88-EDAB-4EF2-9385-85858EBEF229

P2860

Inhibition of both paracrine and autocrine VEGF/ VEGFR-2 signaling pathways is essential to induce long-term remission of xenotransplanted human leukemias

http://www.wikidata.org/entity/Q33943905

description

2001 nî lūn-bûn

@nan

2001 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2001 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2001年の論文

@ja

2001年論文

@yue

2001年論文

@zh-hant

2001年論文

@zh-hk

2001年論文

@zh-mo

2001年論文

@zh-tw

2001年论文

@wuu

name

Inhibition of both paracrine a ...... notransplanted human leukemias

@ast

Inhibition of both paracrine a ...... notransplanted human leukemias

@en

type

label

Inhibition of both paracrine a ...... notransplanted human leukemias

@ast

Inhibition of both paracrine a ...... notransplanted human leukemias

@en

prefLabel

Inhibition of both paracrine a ...... notransplanted human leukemias

@ast

Inhibition of both paracrine a ...... notransplanted human leukemias

@en

P1433

Q33943905-23733E9F-BFCD-451C-BCCE-DBCB668FCA6C

P1476

Q33943905-884BEC73-5773-45A6-B164-B19D85D905AC

P2093

Q33943905-03E49E1D-3A79-42E6-97E5-E2A0F6F07C9B

Q33943905-09C2FC17-5736-4C9C-A7E5-778CFCB10338

Q33943905-41D88819-075C-4152-B2CF-24D878C91CDF

Q33943905-48097C0C-AEE6-460C-BE86-93A63CF31272

Q33943905-634CF19B-406E-40D5-ADD7-52298C03B2AA

Q33943905-6DB12540-7DEC-49B2-A826-A8011CCBEFD5

Q33943905-7689B3DF-A237-4152-95C3-B159EC9B839B

Q33943905-94746947-5799-4A39-9F4A-F4B4CC5574D0

Q33943905-B00F3C4B-7792-4FCD-B590-BCA943D94851

Q33943905-B92C80B2-EACC-4A90-9860-E6B8B0E790DA

P2860

Q33943905-176559AE-F485-49D3-8C83-4F47FA93275E

Q33943905-6688DE56-9784-4BEC-A084-3833D33120C9

Q33943905-6F12D102-BE18-4CF3-8AAB-4EBE677568C6

Q33943905-79099D37-0D2B-44C9-82A1-B304AA6F8BD8

Q33943905-85817667-56B4-47FC-A02A-28A082DC095D

Q33943905-90351C93-A876-4E1E-9666-E1DA398225F4

Q33943905-B7E61AB3-7945-4F91-B951-A9E105611D3C

Q33943905-C2C25C17-8199-4C0A-8553-400485A30E8E

Q33943905-C869CDDB-B4D7-4C54-8D05-5F55D824ED70

Q33943905-D362759A-9825-40C9-99DA-7B43E567AB94

P304

Q33943905-A387F91D-6F7B-4DDF-908D-440EDB15A04F

P31

Q33943905-6C24A3F2-1025-4B0F-8913-51CB0113A2E2

P356

Q33943905-8EEE3785-BA4F-420E-88FA-0F77AB39B081

P407

Q33943905-DA1EAEDB-7EC2-4C71-A928-B94267AFCB81

P433

Q33943905-0CB9B196-323B-4607-98DF-F9D634D2B010

P478

Q33943905-94E3E6D1-EA22-4D6A-9EA2-DC9624C99CF0

P577

Q33943905-C4435D31-FF72-47B6-8329-BC82EDC48333

P5875

Q33943905-9694184D-0FF0-4147-92BD-2F862ACDF024

P698

Q33943905-0A274335-BAB8-4E70-94DE-65A8EC100040

P932

Q33943905-B785F216-08B5-4B47-B4CF-165537E5D146

P356

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Inhibition of both paracrine a ...... notransplanted human leukemias

@en

P2093

B Heissig

http://www.w3.org/2001/XMLSchema#string

D J Hicklin

http://www.w3.org/2001/XMLSchema#string

K Hattori

http://www.w3.org/2001/XMLSchema#string

L Witte

http://www.w3.org/2001/XMLSchema#string

M A Moore

http://www.w3.org/2001/XMLSchema#string

M Tateno

http://www.w3.org/2001/XMLSchema#string

P Bohlen

http://www.w3.org/2001/XMLSchema#string

S Dias

http://www.w3.org/2001/XMLSchema#string

S Rafii

http://www.w3.org/2001/XMLSchema#string

Y Wu

http://www.w3.org/2001/XMLSchema#string

P2860

Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity

Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer

Inhibition of vascular endothelial growth factor induced mitogenesis of human endothelial cells by a chimeric anti-kinase insert domain-containing receptor antibody.

Inhibition of vascular endothelial growth factor-induced receptor activation with anti-kinase insert domain-containing receptor single-chain antibodies from a phage display library.

Regulation of transendothelial migration of hematopoietic progenitor cells.

The role of angiogenesis in tumor growth.

Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia

Production of VEGF and expression of the VEGF receptors Flt-1 and KDR in primary cultures of epithelial and stromal cells derived from breast tumours.

Autocrine stimulation of VEGFR-2 activates human leukemic cell growth and migration

Identification of the residues in the extracellular region of KDR important for interaction with vascular endothelial growth factor and neutralizing anti-KDR antibodies.

P304

10857-10862

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.191117498

http://www.w3.org/2001/XMLSchema#string

P407

P433

19

http://www.w3.org/2001/XMLSchema#string

P478

98

http://www.w3.org/2001/XMLSchema#string

P577

2001-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

235608953

http://www.w3.org/2001/XMLSchema#string

P698

11553814

http://www.w3.org/2001/XMLSchema#string

P932

58564

http://www.w3.org/2001/XMLSchema#string